Navigation Links
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Date:12/8/2007

ATLANTA, GA, December 8, 2007 -- Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma. Data from one study showed that 10 of 21 (48 percent) evaluable patients had a partial or minimal response from the ZOLINZA and bortezomib combination treatment. Data from a second study, sponsored by the United States National Cancer Institute under a Clinical Trials Agreement with Merck & Co., Inc., demonstrated 10 of 23 (43 percent) evaluable patients had a partial response or greater from the combination treatment. These data were presented today at the 49th Annual Meeting of the American Society of Hematology (Abstracts #1168 and #1172).

These trials are the first to evaluate the safety and efficacy of ZOLINZA as part of a combination regimen in patients with relapsed and/or refractory multiple myeloma. The primary objective of both trials was to determine the maximum tolerated dose (MTD) of ZOLINZA in combination with bortezomib in these patients. Bortezomib is regarded as a standard treatment option against multiple myeloma; the use of ZOLINZA in this patient population is investigational.

With more than 50,000 men and women living with multiple myeloma, continued research is imperative, as patients eventually relapse after completing therapy, said Jose Garcia-Vargas, M.D., senior director, Clinical Oncology, Merck Research Laboratories. These data provide a preliminary evaluation of the combination of vorinostat with bortezomib in patients with advanced multiple myeloma, including those who've previously received bortezomib therapy. Larger clinical studies are needed to confirm these results.

Study results

In the multicenter open-label, escalating-dose Phase I trial, a total of 24 patients with relapsed or refractory multiple myeloma were administered oral ZOLINZA 200 mg bid
'/>"/>

Contact: Gina Juliano
gina_juliano@cohnwolfe.com
917-359-5521
Cohn & Wolfe
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...Y., Sept. 5 /PRNewswire/ -- Tonight is a momentous...entertainment industry,executives, celebrities and...advocacy join forces to Stand Up to Cancer. This c...8:00 p.m. to 9:00 p.m. ET on the three,networks --...orm to elevate,the discussion about cancer and the...
(Date:9/5/2008)... /PRNewswire/ -- EthicAd, a nonprofit organization...er education, announces,the launch of a new FDA We...nderstand direct-to-consumer (DTC) advertising of ...t Prescription Drug Advertising," is,hosted by the... was,developed by the FDA in partnership with Ethi...
(Date:9/5/2008)... sorafenib helps reverse disease resistance to ant...HealthDay News) -- The drug sorafenib may help "re...ormonal drugs, Georgetown University Medical Cent...tor or progesterone-receptor positive (ER or PR po...hormonal medicines, such as aromatase inhibitors, ...
(Date:9/5/2008)...cer risk prediction models are enhanced by taking ... DNA repair capacity, according to research teams ...M. D. Anderson Cancer Center in two complementary ... Prevention Research . , In the first study to f...e results based on increased exposure to certain r...
Breaking Medicine News(10 mins):Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3
...squito repellants resembling human body odour whic...t resemble the odour of people who don't get bitte... to prevent the spread of insect-borne diseases su...n developing countries. Some people produce repell...
...hed yesterday for the betterment of the lives of t...s in the midst of a growing concern about the need...tment in Scotland. Charities, the National Rheuma...are have called on the health authorities to ensur...
...ts on banning sugary drinks from schools have met ... Health Minister Pete Hodgson’s idea to make all s... the obesity epidemic has been described as "misgu...ociate Professor Wayne Cutfield and Dr Paul Hofman...
...ty of Oxford have claimed that their study that in... still be very widespread among young children//. ... cough, which is also known as ‘Pertussis’. This b... killer with reports of almost 100,000 cases a yea...
Other Medicine News:Health News:Campaign For Arthritis Awareness Launched In Scotland 2Health News:Anti-Obesity Groups Criticize Response of Medical Professionals 2Health News:Researchers Warn That Whooping Cough Is Still Very Prevalent 2Health News:Researchers Warn That Whooping Cough Is Still Very Prevalent 3
(Date:9/4/2008)...INGHAM, Ala., Sept. 4 /- Southern Res...Institutes of Health (NIH) has selected,the organi...r Libraries,Probe Production Center Network (MLPCN...- is part of the Molecular Libraries Program which...ntific knowledge of the human,genome and validate ...
(Date:9/4/2008)... cohort demonstrates potent antiviral activity and...ofile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-Fi... IDIX ), a biopharmaceutical company engaged,in th...ment of human viral,and other infectious diseases,...f-concept study evaluating IDX899, a non-nucleosid...
(Date:9/3/2008)...ays: Wrong Question Asked. Wrong Children Studied....PRNewswire-USNewswire/ -- A Centers for Disease,Co...aims there is no link,between the MMR vaccine and ... this study does nothing to dispel the growing pub...aises several questions concerning design,and meth...
(Date:9/3/2008)... September is National Vascular Disease Awarenes...e/ -- Diffusion Pharmaceuticals,LLC, a clinical-st...rugs,for the treatment of unmet medical needs, ann...in a Phase I/II clinical trial of its lead drug,ca... designated NCT00725881,on the clinicaltrials.gov ...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4China Clean Energy Updates Business Outlook 6279 1China Clean Energy Updates Business Outlook 6279 2China Clean Energy Updates Business Outlook 6279 3New York Resident Elected President of Lions Clubs International 22871 1New York Resident Elected President of Lions Clubs International 22871 2Medical Machines Online Announces the Overstock and Release of a New ECG Machine 22868 1Medical Machines Online Announces the Overstock and Release of a New ECG Machine 22868 2Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 22865 1Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 22865 2
...nts with,predominantly classic subfoveal choroid... the Opal Photoactivator from,Lumenis. Developed...or injection) therapy, the Opal Photoactivator,o...tures,that ensure the highest level of patient c...
Features soft, low friction sheath that extends beyond the tip.
Designed to retain the desired curve during oral intubation.
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box.
Medicine Products: